Dear Research Advocate, I don’t like to start letters with disappointing news, but it’s best to get to the heart of things. This week the Biden Administration released a budget proposal for Fiscal Year 2023 (FY23) that would provide grossly insufficient funding for NIH. The proposed 0.6% increase will not p osition our nation to address longstanding, emerging, and yet-unknown health threats, nor bolster our research capacity to ensure global competitiveness. As a reminder, the President’s budget is a statement of Administration priorities that begins the appropriations process. Congress will be deeply involved in its execution, and we are confident our alliance and other NIH advocates can...
Dear Research Advocate, “This is a moment of phenomenal exponential opportunity in biomedical research,” said Francis Collins, MD, PhD, at last week’s 2022 Advocacy Awards , as he was honored with the John Edward Porter Legacy Award . In a candid conversation with Kizzmekia S. Corbett, PhD, Dr. Collins discussed not just the discoveries on the horizon, but his legacy, the challenges of trust in science exacerbated by a pandemic, and the value of both storytelling and faith, among a host of other topics. We didn’t have time to air the entire Corbett/Collins discussion during the Awards program, but the full 24-minute chat is now available. On the Hill: Congress is making headway on two...
Dear Research Advocate, “The cost is billions. The return is trillions, and it's priceless to patients and their families.” This characterization of the life-saving research NIH supports and conducts by Jed Manocherian, ACT for NIH Chairman and Founder, is emblematic of the affecting and thought-provoking discussions that took place throughout yesterday’s 2022 Advocacy Awards. (We were honored to recognize Jed with the Gordon and Llura Gund Leadership Award for his unparalleled NIH advocacy. If you couldn’t join us “live,” check out this high-level recap of the program and watch the full event . We’d like to again express our appreciation to the honorees themselves, to the award benefactors...
Dear Research Advocate, Countdown: Research!America’s 2022 Advocacy Awards program is less than a week away. If you haven’t already, register now to join this virtual program, taking place Wednesday, March 16, from 4 – 6 p.m. ET. In a series of informal conversations, we’ll hear from our honorees and such guests as Congressman Tom Cole (R-OK) , Congressman Kweisi Mfume (D-MD), and Senator Barbara Mikulski (Ret.). There is so much to highlight, but as our nation continues to take in the enormity of the pandemic still upon us, let me call out our Outstanding Achievement in Public Health Awards , generously supported by Johnson & Johnson. Public health extends far beyond one pandemic, as...
World Glaucoma Week is a global initiative being held March 6-12 , to raise awareness on glaucoma with events happening around the world. As one of those events, the Alliance for Eye and Vision Research (AEVR) is excited to present the Understanding Glaucoma Patients: Health Disparities and Unmet Need Virtual Congressional Briefing on Wednesday, March 8. AEVR worked with Research!America on the Vision and Blindness fact sheet in the past to provide useful information about eye disease and vision impairment, including the latest research into glaucoma. Americans fear vision loss more than most other medical conditions, as reported in a 2014 Research!America poll conducted for AEVR. 1 The...
Dear Research Advocate, President Biden opened his State of the Union address by condemning Russia’s unprovoked invasion of Ukraine and commending the bravery and resilience of the Ukrainian people. Turning next to the economy, he emphasized the vital role of federal R&D and public-private partnerships in creating jobs, assuring better health, and driving global competitiveness. As part of his “unity agenda” he called on Congress to take specific steps to address the opioid epidemic, mental illness, veterans’ well-being, and cancer. He also urged Congress to complete work on bipartisan competitiveness legislation and called for the establishment of ARPA-H ( see our statement and an...
This piece reflects the opinions of the author. Genomic testing can drastically reduce the waiting time in the diagnosis of genetic disorders, not only saving lives, but money. These services, including rapid whole genome sequencing (rWGS), should be a standard of care for infants presenting with symptoms or screening results that suggest the possibility of a deadly or debilitating condition. The infant mortality rate (IMR) in the United States is 5.7 per 1,000 births, which places our nation near the bottom (33rd) when ranked against 37 other OECD countries. In the United States, the top reasons for infant death and hospitalization are congenital anomalies and genetic disorders, affecting...

Sidebar Quote

Luck shouldn't play a role in why I'm alive.
Laurie MacCaskill, a seven-year pancreatic cancer survivor